Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.
Neuren Pharmaceuticals Limited announced the issuance of 1,800,000 unquoted securities under an employee share scheme, effective May 23, 2025. This move is part of the company’s strategy to incentivize and retain talent, potentially impacting its operational dynamics and aligning employee interests with shareholder value.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$30.65 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company is known for its work on treatments that address conditions such as Rett syndrome and Fragile X syndrome, targeting significant unmet medical needs in these areas.
Average Trading Volume: 772,549
Technical Sentiment Signal: Hold
Current Market Cap: A$1.63B
For an in-depth examination of NEU stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue